Novavax’s COVID-19 vaccine has been shown to be highly effective against moderate and severe disease — including in high-risk groups, such as over-65s and those with comorbidities — trial results show.

The long-awaited pivotal phase III data for the recombinant protein subunit vaccine known as NVX-CoV2373, which are not yet published, show an overall efficacy of 90% against the coronavirus, the company has announced.

At the same time, Novavax has published the first co-administration study of a COVID-19 vaccine with influenza inoculation, demonstrating immunogenicity is preserved for both vaccines.

The Australian Government has signed a deal to buy 51 million doses of the investigational Novavax COVID-19 vaccine if it is approved by the TGA, which began its ‘rolling assessment’ earlier this year.